Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Chinese Journal of Gastrointestinal Surgery ; (12): 466-470, 2022.
Artigo em Chinês | WPRIM | ID: wpr-936104

RESUMO

With the increasing detection rate of early upper gastric cancer and adenocarcinoma of esophagogastric junction, the safety of proximal gastrectomy with clear indications has been verified, and function-preserving proximal gastrectomy has been widely used. However, proximal gastrectomy destructs the normal anatomical structure of esophagogastric junction, resulting in severe postoperative gastroesophageal reflux symptoms and seriously affecting the quality of life. Among various anti-reflux surgery methods, reconstruction of "cardiac valve" has always been the focus of relevant scholars because its similarity with the mechanism of normal anti-reflux. After years of development, evolution and optimization, the designed seromuscular flap anastomosis includes tunnel muscle flap anastomosis, Hatafuku valvuloplasty, single muscle flap anastomosis and double muscle flap anastomosis. The double muscle flap anastomosis has become a research hotspot because it shows good anti-reflux effect in clinical application. This paper reviews the history, research status and hot issues of seromuscular flap anastomosis of esophageal remnant stomach at home and abroad.


Assuntos
Humanos , Anastomose Cirúrgica/métodos , Junção Esofagogástrica/cirurgia , Gastrectomia/métodos , Refluxo Gastroesofágico/cirurgia , Qualidade de Vida , Neoplasias Gástricas/cirurgia
2.
Chinese Medical Journal ; (24): 320-325, 2016.
Artigo em Inglês | WPRIM | ID: wpr-310658

RESUMO

<p><b>BACKGROUND</b>Thalidomide is an immunomodulatory and anti-angiogenic drug that has shown promise in patients with myeloma. Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence. This meta-analysis aimed to determine the efficacy and toxicity of thalidomide in previously untreated elderly patients with myeloma.</p><p><b>METHODS</b>Medline, the Cochrane Controlled Trials register, conference proceedings of the American Society of Hematology (1995-2014), the American Society of Clinical Oncology (1995-2014), and CBM, VIP, and CNKI databases were searched for randomized control trials with the use of the medical subject headings "MM " and "thalidomide ". Trials were assessed by two reviewers for eligibility. Meta-analysis was conducted using a fixed effects model. Sensitivity analysis was performed to test the robustness of the findings.</p><p><b>RESULTS</b>Overall, seven trials were identified, covering a total of 1821 subjects. The summary hazard ratio (thalidomide vs. control) was 0.82 (95% confidence interval [CI]: 0.72-0.94) for overall survival (OS), and 0.65 (95% CI: 0.58-0.73) for progression-free survival, in favor of thalidomide treated group. The risk ratio of complete response with induction thalidomide was 3.48 (95% CI: 2.24-5.41). A higher rate of III/IV adverse events were observed in MPT arm compared with the MP arm. However, analysis of sub-groups administering anticoagulation as venous thromboembolism prophylaxis suggested no difference in relative risk of thrombotic events between two arms (RR = 1.47, 95% CI: 0.43-5.07, P = 0.54). Further analysis of trials on the treatment effects of MPT versus MP on adverse events-related mortality showed no statistical difference between two arms (RR = 1.24, 95% CI: [0.95-1.63], P = 0.120).</p><p><b>CONCLUSION</b>Thalidomide appears to improve the OS of elderly and/or transplant-ineligible patients with MM when it is added to standard MP therapy.</p>


Assuntos
Humanos , Intervalo Livre de Doença , Imunossupressores , Usos Terapêuticos , Melfalan , Usos Terapêuticos , Mieloma Múltiplo , Tratamento Farmacológico , Mortalidade , Prednisona , Usos Terapêuticos , Talidomida , Usos Terapêuticos
3.
Journal of International Pharmaceutical Research ; (6): 807-812, 2013.
Artigo em Chinês | WPRIM | ID: wpr-845865

RESUMO

Objective To evaluate the antimicrobial activity and establish HPLC fingerprint of flavonoids in Flos Chrysanthemi Indici. Methods Microdilution method was carried out to determine the minimum inhibitory concentration (MIC) value of total flavonoids and linarin against eleven kinds of bacteria and three fungi. HPLC fingerprint was obtained on Diamonsil C18 (4. 6 mm × 250 mm, 3 μ,m) with gradient elution consisting of acetonitrile (A) and 0. 05% phosphoric acid (B), detective wavelength was at 326 nm and flow rate 1. 0 ml/min n he room temperature. The data were analyzed by Computer Aided Similarity Evaluation software. Results MIC values of total flavonoids and inarin against Candida lusitaniae were 61. 6 μg/ml and 18. 0 μg/ml, respectively. Furthermore, fifteen characteristic peaks were indicated n fingerprint chromatography, and eight peaks were identified as flavonoids. Conclusion Total flavonoids and he inarin n Flos Chrysanthemi Indici exhibited better antimicrobial activity against C. lusitaiae. The established HPLC fingerprint method s accurate and reproducible, and can be used for the basic research and quality control of active flavonoids in Flos Chrysanthemi Indici.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA